Skip to content
Agree.net – Lifestyle
Author:
Spago Nanomedical
Spago Nanomedical’s Phase I/IIa study Tumorad-01 Meets a Primary Endpoint and Provides Further Visible Tumor Uptake
May 6, 2026
←
Previous Page
1
2